The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
PURPOSE: We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of oxaliplatin-induced neurotoxicity. PATIENTS AND METHODS: Fifty-two patients treated with a bimonthly oxaliplatin-based regimen were randomized to receive GSH (1,500 mg/m 2 over a 15-minute infusion period before oxaliplatin) or normal saline solution. Clinical neurologic evaluation and electrophysiologic investigations were performed at baseline and after four (oxaliplatin dose, 400 mg/m 2), eight (oxaliplatin dose, 800 mg/m 2), and 12 (oxaliplatin dose, 1,200 mg/m 2) cycles of treatment. RESULTS: At the fourth cycle, seven patients showed clinically evident neuropathy in the GSH arm, whereas 11 patients in the placebo arm did. After the eighth cycle, nine of 21 assessable patients in the GSH arm suffered from neurotoxicity compared with 15 of 19 in the placebo arm. With regard to grade 2 to 4 National Cancer Institute common toxicity criteria, 11 patients experienced neuropathy in the placebo arm compared with only two patients in the GSH arm (P = .003). After 12 cycles, grade 2 to 4 neurotoxicity was observed in three patients in the GSH arm and in eight patients in the placebo arm (P = .004). The neurophysiologic investigations (sural sensory nerve conduction) showed a statistically significant reduction of the values in the placebo arm but not in the GSH arm. The response rate was 26.9% in the GSH arm and 23.1% in the placebo arm, showing no reduction in activity of oxaliplatin. CONCLUSION: This study provides evidence that GSH is a promising drug for the prevention of oxaliplatin-induced neuropathy, and that it does not reduce the clinical activity of oxaliplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Glantz, S. A. (1981) · Cited by 2,636
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F., Jasmin, C., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008347829017 · Cited by 606
Charles F. Kettring prize. Fundamental studies with cisplatin
Rosenberg, B. (1985) · Cancer · doi:10.1002/1097-0142(19850515)55:10<2303::aid-cncr2820551002>3.0.co;2-l · Cited by 517
Regulation of fast inactivation of cloned mammalian IK(A) channels by cysteine oxidation
Ruppersberg, J. P., Stacker, M., Pongs, O., Heinemann, S. H., Frank, R., & Koenen, M. (1991) · Nature · doi:10.1038/352711a0 · Cited by 447
Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies
Thompson, S. W., Davis, L. E., Kornfeld, M., Hilgers, R. D., & Standefer, J. C. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1269::aid-cncr2820540707>3.0.co;2-9 · Cited by 394
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., Elderson, A., Boogerd, W., Heimans, J. J., Vries, E. P., van Houwelingen, J. C., Jennekens, F. G. I., Gispen, W. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 287
Cited by
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
Chemotherapy for advanced gastric cancer
Wagner, A. D., Syn, N. L., Moehler, M., Grothe, W., Yong, W. P., Tai, B.-C., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,299
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A. D., Brezault, C., Le Charpentier, M., Dousset, B., Morel, P., Soubrane, O., Chaussade, S., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh095 · Cited by 1,038
Reactive oxygen species and cancer paradox: To promote or to suppress?
Galadari, S., Rahman, A., Pallichankandy, S., & Thayyullathil, F. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.004 · Cited by 893
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 648
Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies
Wolf, S., Barton, D., Kottschade, L., Grothey, A., & Loprinzi, C. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.04.018 · Cited by 632
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?
Lawenda, B. D., Kelly, K. M., Ladas, E. J., Sagar, S. M., Vickers, A., & Blumberg, J. B. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn148 · Cited by 472
Verstappen, C. C. P., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003) · Drugs · doi:10.2165/00003495-200363150-00003 · Cited by 456
Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy
Areti, A., Yerra, V. G., Naidu, V., & Kumar, A. (2014) · Redox Biology · doi:10.1016/j.redox.2014.01.006 · Cited by 456
Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.010 · Cited by 408
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.160 · Cited by 351
A review on oxaliplatin-induced peripheral nerve damage
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330
Block, K. I., Koch, A. C., Mead, M. N., Tothy, P. K., Newman, R. A., & Gyllenhaal, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23754 · Cited by 328
Free radicals and antioxidants in chemotherapyinduced toxicity
Weijl, N. I., Cleton, F. J., & Osanto, S. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90012-8 · Cited by 325
The Challenges of Colorectal Cancer Survivorship
Denlinger, C. S., & Barsevick, A. M. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0058 · Cited by 324
Oxaliplatin-safety profile: neurotoxicity
GROTHEY, A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00399-3 · Cited by 319
Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy
Pace, A., Savarese, A., Picardo, M., Maresca, V., Pacetti, U., Del Monte, G., Biroccio, A., Leonetti, C., Jandolo, B., Cognetti, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.139 · Cited by 307
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub4 · Cited by 298
Singh, K., Bhori, M., Kasu, Y. A., Bhat, G., & Marar, T. (2018) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.12.013 · Cited by 288
Troublesome Symptoms in Cancer Survivors: Fatigue, Insomnia, Neuropathy, and Pain
Pachman, D. R., Barton, D. L., Swetz, K. M., & Loprinzi, C. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.7238 · Cited by 282
Gill, J. S., & Windebank, A. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1130 · Cited by 278
Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)
Han, Y., & Smith, M. T. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00156 · Cited by 273
Chemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
Pachman, D. R., Barton, D. L., Watson, J. C., & Loprinzi, C. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.115 · Cited by 268
Oxaliplatin-Associated Neuropathy: A Review
Cersosimo, R. J. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e319 · Cited by 268
Oxaliplatin-related neurotoxicity: How and why?
Pasetto, L. M., D’Andrea, M. R., Rossi, E., & Monfardini, S. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.01.001 · Cited by 267
Evidence of Toxicity, Oxidative Stress, and Neuronal Insult in Autism
Kern, J. K., & Jones, A. M. (2006) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937400600882079 · Cited by 265
Hershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., Awad, D., & Crew, K. D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1278-0 · Cited by 264
Docetaxel-related side effects and their management
Baker, J., Ajani, J., Scotté, F., Winther, D., Martin, M., Aapro, M. S., & von Minckwitz, G. (2009) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2008.10.003 · Cited by 261
Liu, Y.-Q., Wang, X.-L., He, D.-H., & Cheng, Y.-X. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153402 · Cited by 259
The Odyssey of Bioactive Compounds in Avocado (Persea americana) and Their Health Benefits
Bhuyan, D. J., Alsherbiny, M. A., Perera, S., Low, M., Basu, A., Devi, O. A., Barooah, M. S., Li, C. G., & Papoutsis, K. (2019) · Antioxidants · doi:10.3390/antiox8100426 · Cited by 259
NCCN Task Force Report: Management of Neuropathy in Cancer
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., Junck, L., Morris, G. S., Paice, J. A., Tummala, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0078 · Cited by 257
Cisplatin-Associated Nephrotoxicity and Pathological Events
Taguchi, T., Nazneen, A., Abid, M. R., & Razzaque, M. S. (2005) · Contributions to Nephrology · doi:10.1159/000086055 · Cited by 256
Metadata
- Authors
- Cascinu, S., Catalano, V., Cordella, L., Labianca, R., Giordani, P., Baldelli, A. M., Beretta, G. D., Ubiali, E., & Catalano, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-08-15
- Volume
- 20
- Issue
- 16
- Pages
- 3478-3483
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2006613730
- Cited by
- 421
- References
- 22
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.